Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ESSA PharmaKaryopharm TherapeuticsG1 TherapeuticsProthenaVeru
SymbolNASDAQ:EPIXNASDAQ:KPTINASDAQ:GTHXNASDAQ:PRTANASDAQ:VERU
Price Information
Current Price$24.82$9.71$23.51$24.85$9.42
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.71.52.11.4
Analysis Score2.53.43.53.53.5
Community Score3.13.02.42.82.9
Dividend Score0.00.00.00.00.0
Ownership Score2.51.71.73.30.0
Earnings & Valuation Score0.00.60.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$28.80$29.88$49.17$29.43$19.20
% Upside from Price Target16.04% upside207.67% upside109.13% upside18.42% upside103.82% upside
Trade Information
Market Cap$838.42 million$728.84 million$986.46 million$994.15 million$677.41 million
Beta1.960.932.441.710.71
Average Volume360,3792,554,3441,520,257460,1583,806,419
Sales & Book Value
Annual RevenueN/A$40.89 millionN/A$810,000.00$42.59 million
Price / SalesN/A17.82N/A1,227.3415.91
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.47 per share$0.79 per share$6.80 per share$6.84 per share$0.43 per share
Price / BookN/A12.29N/A3.6321.91
Profitability
Net Income$-23,440,000.00$-199,590,000.00$-122,450,000.00$-77,680,000.00$-18,970,000.00
EPS($1.04)($3.22)($3.27)($1.95)($0.11)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-221.23%N/A-13,615.75%-44.55%
Return on Equity (ROE)-46.31%-187.66%-49.35%-41.97%-23.72%
Return on Assets (ROA)-45.08%-56.42%-41.53%-26.26%-13.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.38%0.10%N/AN/A
Current Ratio66.75%5.42%7.45%14.75%1.83%
Quick Ratio66.75%5.39%7.45%14.75%1.38%
Ownership Information
Institutional Ownership Percentage63.37%88.56%77.89%90.15%23.32%
Insider Ownership PercentageN/A13.26%14.49%30.40%26.10%
Miscellaneous
Employees2543212266339
Shares Outstanding33.78 million75.06 million41.96 million40.01 million71.91 million
Next Earnings Date5/6/2021 (Estimated)5/4/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Estimated)5/12/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
SpaceX wins U.S. contract for spacecraft to send astronauts to moon -Washington Post - Yahoo FinanceSpaceX wins U.S. contract for spacecraft to send astronauts to moon -Washington Post - Yahoo Finance
finance.yahoo.com - April 17 at 1:55 PM
 Analysts Anticipate Veru Inc. (NASDAQ:VERU) Will Announce Earnings of -$0.03 Per Share Analysts Anticipate Veru Inc. (NASDAQ:VERU) Will Announce Earnings of -$0.03 Per Share
americanbankingnews.com - April 17 at 2:14 AM
Goldman Sachs communications head Jake Siewert to leave - NYT - Yahoo FinanceGoldman Sachs communications head Jake Siewert to leave - NYT - Yahoo Finance
finance.yahoo.com - April 17 at 12:12 AM
Inflation a Bigger Risk Than Recession: Quadratics Davis - Yahoo FinanceInflation a Bigger Risk Than Recession: Quadratic's Davis - Yahoo Finance
finance.yahoo.com - April 17 at 12:12 AM
Moscow to ask 10 U.S. diplomats to leave Russia - foreign minister - Yahoo FinanceMoscow to ask 10 U.S. diplomats to leave Russia - foreign minister - Yahoo Finance
finance.yahoo.com - April 17 at 12:12 AM
Western governments condemn attacks in northern Iraq - Yahoo FinanceWestern governments condemn attacks in northern Iraq - Yahoo Finance
finance.yahoo.com - April 16 at 7:11 PM
DLR Kredit A/S - endelige obligationsvilkår (DK0006352786 - 1,5% B 2053) - Yahoo FinanceDLR Kredit A/S - endelige obligationsvilkår (DK0006352786 - 1,5% B 2053) - Yahoo Finance
finance.yahoo.com - April 16 at 7:11 PM
Insurer Hartford to pay $650 million for claims linked to Boy Scouts of America sex abuse cases - Yahoo FinanceInsurer Hartford to pay $650 million for claims linked to Boy Scouts of America sex abuse cases - Yahoo Finance
finance.yahoo.com - April 16 at 7:11 PM
2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential - Nasdaq2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential - Nasdaq
nasdaq.com - April 16 at 7:11 PM
2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential - Report Door2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential - Report Door
reportdoor.com - April 16 at 2:11 PM
Doctor: COVID-19 vaccines do lead to a really strong immune response - Yahoo FinanceDoctor: COVID-19 vaccines 'do lead to a really strong immune response' - Yahoo Finance
finance.yahoo.com - April 16 at 2:11 PM
Jefferies Financial Group Comments on Veru Inc.s Q2 2021 Earnings (NASDAQ:VERU)Jefferies Financial Group Comments on Veru Inc.'s Q2 2021 Earnings (NASDAQ:VERU)
americanbankingnews.com - April 15 at 6:38 AM
Analyzing The Price Action In Veru Stock Today - BenzingaAnalyzing The Price Action In Veru Stock Today - Benzinga
benzinga.com - April 13 at 8:56 PM
Jim Cramer: Novocure, Veru, and Regeneron - Buy, Sell, or Hold - TheStreetJim Cramer: Novocure, Veru, and Regeneron - Buy, Sell, or Hold - TheStreet
thestreet.com - April 13 at 3:56 PM
Is Veru Inc (VERU) a Smart Choice in Biotechnology Tuesday? - InvestorsObserverIs Veru Inc (VERU) a Smart Choice in Biotechnology Tuesday? - InvestorsObserver
investorsobserver.com - April 13 at 3:56 PM
Veru (NASDAQ:VERU) Shares Gap Up to $9.76Veru (NASDAQ:VERU) Shares Gap Up to $9.76
americanbankingnews.com - April 13 at 11:10 AM
Veru (NASDAQ:VERU) Coverage Initiated at Jefferies Financial GroupVeru (NASDAQ:VERU) Coverage Initiated at Jefferies Financial Group
americanbankingnews.com - April 13 at 9:16 AM
Movie actors and politicians for hire in Madurai - Daijiworld.comMovie actors and politicians for 'hire' in Madurai - Daijiworld.com
daijiworld.com - April 12 at 1:58 PM
Global Mediterranean Fever Treatment Market Size, Share, Key Drivers, Growth Factors, Demands, Top Manufacturers-Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Takeda Pharmaceutical Company Limited – ROUGH Magazine - ROUGH MagazineGlobal Mediterranean Fever Treatment Market Size, Share, Key Drivers, Growth Factors, Demands, Top Manufacturers-Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Takeda Pharmaceutical Company Limited – ROUGH Magazine - ROUGH Magazine
rough.asia - April 12 at 1:58 PM
Announcements - April 11, 2021 - Times of MaltaAnnouncements - April 11, 2021 - Times of Malta
timesofmalta.com - April 12 at 1:58 PM
Are Options Traders Betting on a Big Move in Veru (VERU) Stock? - Yahoo FinanceAre Options Traders Betting on a Big Move in Veru (VERU) Stock? - Yahoo Finance
finance.yahoo.com - April 5 at 9:09 AM
Are Options Traders Betting on a Big Move in Veru (VERU) Stock?Are Options Traders Betting on a Big Move in Veru (VERU) Stock?
finance.yahoo.com - April 5 at 9:09 AM
Veru Inc. (NASDAQ:VERU) Receives Average Recommendation of "Buy" from BrokeragesVeru Inc. (NASDAQ:VERU) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - April 3 at 6:40 AM
Veru Inc. (NASDAQ:VERU) Short Interest UpdateVeru Inc. (NASDAQ:VERU) Short Interest Update
americanbankingnews.com - April 1 at 6:48 AM
Mid Growth Stock Returns Of 0.2% Last Week Beat Those Of Low Growth, High Growth, Very High Growth Stocks (3/29/2021 ) - TrefisMid Growth Stock Returns Of 0.2% Last Week Beat Those Of Low Growth, High Growth, Very High Growth Stocks (3/29/2021 ) - Trefis
trefis.com - March 30 at 1:12 AM
DateCompanyBrokerageAction
3/10/2021ESSA PharmaPiper SandlerInitiated Coverage
3/3/2021ESSA PharmaHC WainwrightLower Price Target
2/12/2021ESSA PharmaBloom BurtonReiterated Rating
2/11/2021ESSA PharmaOppenheimerBoost Price Target
11/2/2020ESSA PharmaJefferies Financial GroupInitiated Coverage
4/11/2021Karyopharm TherapeuticsRoyal Bank of CanadaReiterated Rating
2/12/2021Karyopharm TherapeuticsBarclaysLower Price Target
2/11/2021Karyopharm TherapeuticsSVB LeerinkLower Price Target
11/3/2020Karyopharm TherapeuticsMorgan StanleyLower Price Target
7/14/2020Karyopharm TherapeuticsRobert W. BairdSet Price Target
6/23/2020Karyopharm TherapeuticsJPMorgan Chase & Co.Boost Price Target
6/23/2020Karyopharm TherapeuticsWedbushBoost Price Target
5/6/2020Karyopharm TherapeuticsCanaccord GenuityReiterated Rating
4/9/2021G1 TherapeuticsNeedham & Company LLCReiterated Rating
11/17/2020G1 TherapeuticsRaymond JamesDowngrade
8/9/2020G1 TherapeuticsCowenReiterated Rating
6/26/2020G1 TherapeuticsRoth CapitalInitiated Coverage
1/7/2020G1 TherapeuticsBTIG ResearchBoost Price Target
10/21/2020ProthenaCantor FitzgeraldBoost Price Target
5/10/2020ProthenaNomuraReiterated Rating
1/1/2020ProthenaNomura SecuritiesReiterated Rating
12/22/2019ProthenaEvercore ISIReiterated Rating
12/14/2020VeruBrookline Capital ManagementBoost Price Target
3/20/2019VeruCIBCInitiated Coverage
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.